Skip to main content
OpenTrials
Completed

NCT Number: NCT01192035

PI or NNRTI as First-line Treatment of HIV in West Africa - the PIONA Trial

BACKGROUND: Since 1996 the combination of three or more drugs has been the mainstay of human immunodeficiency virus (HIV) treatment. The most important types of drugs are called nucleotide reverse transcriptase inhibitors (NRTIs), non-nucleotide reverse transcriptase inhibitors (NNRTIs) and protease inhibitors (PIs) Response to treatment is measured as increasing CD4+ cell count and decreasing HIV viral load. A major problem is the development of resistance. NNRTIs are recommended as part of first-line treatment of HIV in Africa but many Africans have a slower NNRTI clearance than Caucasians making them more susceptible for development of resistance in case of treatment interruptions. PIs might therefore be a better option in an African setting with low adherence.

AIM: To evaluate two different treatment regimens in HIV-1 infected patients:

A) A NNRTI (efavirenz/nevirapine) based regimen and B) A PI (ritonavir-boosted lopinavir) based regimen with regard to treatment outcomes. HYPOTHESIS: Treatment with a PI will be superior to treatment with a NNRTI due to less development of resistance.

METHODS: Treatment-naïve adult HIV-1 patients enrolled in an existing cohort The West African Retrovirus and Acquired Immune Deficiency (WARAID) cohort in Guinea Bissau with CD4+ cell count ≤ 350 cells/µL and/or clinical signs of immune suppression (World Health Organization (WHO) clinical stage 3 or 4) will be randomised 1:1 to: Treatment A: 2 NRTIs (lamivudine and either zidovudine or stavudine) and 1 NNRTI (efavirenz or nevirapine) or Treatment B: 2 NRTIs (same as in treatment A) and 1 PI (ritonavir-boosted lopinavir). Primary outcome: Viral load suppression <400 copies/ml 12 months after enrolment.

PERSPECTIVES: Guidelines for treatment of HIV in Africa are more or less a copy of the guidelines used in Europe and North America. Genetic differences in pharmacokinetics, more women infected in Africa and difficulties ensuring good adherence mean that results obtained from Caucasian patients are not directly transferrable to African patients. The results of this study will hopefully help guiding the treatment of HIV in Africa in the future. The investigators believe the HIV infected people in West Africa deserve the same evidence-based medicine as in developed countries.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

HIV-1

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Centro de Tratamento Ambulatoria do Hospital Nacional Simão Mendes

Bissau, Guinea-Bissau

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Antiretroviral treatment (ART) naïve HIV-1 infected patients. Women receiving ART during pregnancy can be included.
  • Age ≥ 18 years
  • CD4+ cell count ≤ 350 cells/µL and/or
  • Clinical signs of immune suppression (WHO clinical stage 3 or 4) irrespective of CD4+ cell count.

Exclusion criteria

  • Tuberculosis (TB) treatment with rifampicin at the time of enrolment.
  • Co-infection with HIV-2.
  • Grade 3 or 4 alanine transaminase (ALAT) elevation (>5 times upper normal limit).
  • Patients with cerebral disturbances that complicates the ability to give informed consent or follow the treatment regime.

Treatment and study plan

Efavirenz or Nevirapine

Drug

2 NRTIs (lamivudine 150 mg "bis in die - twice a day" (BID) and either zidovudine 300 mg BID if hemoglobin is ≥ 8 g/L or stavudine 30 mg BID if hemoglobin is < 8 g/L) and 1 NNRTI (efavirenz 600 mg "omne in die - once daily" (OD) or nevirapine 200 mg OD for the first 2 weeks and after that 200 mg BID). Efavirenz will be used in all male patients according to national HIV guidelines. Pregnant patients and female patients with a child bearing potential will be treated with nevirapine if CD4+ cell count is ≤ 350 cells/mm3 with close monitoring of liver enzymes during the first 12 weeks in patients with CD4+ cell count >250 cells/mm3. Females beyond childbearing age will be treated with efavirenz.

Other names: Stocrin, Sustiva, Viramune

Ritonavir-boosted lopinavir

Drug

2 NRTIs (lamivudine 150 mg BID and either zidovudine 300 mg BID if hemoglobin is ≥ 8 g/L or stavudine 30 mg BID if hemoglobin is < 8 g/L) and 1 PI (ritonavir-boosted lopinavir 400/100 mg BID).

Other names: Kaletra, Aluvia

Primary outcomes

  1. Fraction of patients with viral load suppression <400 copies/ml

    Time frame: 12 months after enrolment

Secondary outcomes

  1. Fraction of patients with viral load suppression <50 copies/ml

    Time frame: 12 months after enrolment

  2. Increment of CD4+ cell count of at least 100 cells/µL

    Time frame: 12 months after enrolment

  3. Development of ≥1 resistance mutations involving the treatment regimens used in patients with viral load >400 copies/ml

    Time frame: 12 months after enrolment

  4. Frequency of adverse events and severe adverse events

    Time frame: Within 12 months

  5. Compliance.

    Time frame: Within 12 months

    Compliance defined as the actual amount of medicine taken compared to the planned amount for the same treatment period. A pill count is carried out at each visit.

  6. Incidence of tuberculosis.

    Time frame: Within 12 months

  7. Death.

    Time frame: Within 12 months

    Death at 12 month follow-up. Any patient lost to follow-up will be attempted visited at home by a field assistant 1 month after latest visit due. Information on patient death from family or neighbors will be recorded as a mortality event and a verbal autopsy conducted.

  8. Weight

    Time frame: Within 12 months

    Increase in body mass index (BMI) and frequency of severe weight loss (>10% of presumed or measured body weight).

  9. Plasma cytokine levels

    Time frame: Within 12 months

Sponsors and collaborators

Lead sponsor

University of Aarhus

Other

Collaborators

  • Aarhus University Hospital Skejby
  • Abbott
  • Bandim Health Project
  • Ministry of Public Health, Guinea-Bissau

Registry information

Official study title

PI or NNRTI as First-line Treatment of HIV in a West African Population With Low Adherence - the PIONA Trial

Acronym: PIONA

Important dates

Study start
2011
Primary completion
2014
Study completion
2014
First posted
Aug 31, 2010
Registry last updated
Jun 25, 2015

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.